Navigation Links
Epizyme, Inc. Provides Third Quarter 2013 Financial Results and Corporate Update
Date:10/22/2013

6. This is the first composition of matter patent for EPZ-5676 and, once issued, this patent will expire in 2032. Also in September 2013, the USPTO issued U.S. Patent No. 8,524,467 titled "Diagnostic and Therapeutic Targets for Leukemia," with claims directed to methods of identifying DOT1L inhibitor compounds for the treatment of leukemia. This patent expires in 2030.

Third Quarter 2013 Financial Results & Financial Guidance

  • Cash Position: Cash and cash equivalents as of September 30, 2013, were $139.6 million, compared to $98.0 million as of December 31, 2012. The cash increase was driven by net proceeds of $82.5 million from Epizyme's initial public offering in June 2013 and a $6 million milestone achieved in June 2013 from the Eisai collaboration for the initiation of the EPZ-6438 Phase 1/2 study.
  • Revenue: Collaboration revenue was $8.4 million for the third quarter of 2013 and $32.2 million for the nine months ended September 30, 2013, compared to $15.3 million and $36.3 million for the comparable periods in 2012. Collaboration revenue includes deferred revenue from payments received in previous periods as well as payments received and recognized during the respective periods.
  • R&D Expenses: Research and development expenses were $14.6 million for the third quarter of 2013 and $41.9 million for the nine months ended September 30, 2013, compared to $9.3 million and $27.4 million for the comparable periods in 2012. The increase was largely driven by the expansion of Epizyme's product platform and costs for the clinical studies of EPZ-5676 and EPZ-6438.
  • G&A Expenses: General and administrative expenses were $3.6 million for the third quarter of 2013 and $9.7 million for the nine months ended September 30, 2013, compared to $1.6 million and $5.2 million for the comparable periods in 2012. The increase was largely driven by incremental expenses to support public company operations as well as increased st
    '/>"/>

  • SOURCE Epizyme, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Epizyme, Inc. Reports Second Quarter 2013 Financial Results
    2. New Resource Provides Herb Industry With Sources of Quality Specifications
    3. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
    4. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
    5. Health Diagnostic Laboratory, Inc. Provides Largest Corporate Gift in Science Museum of Virginias History
    6. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
    7. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
    8. Insmed Incorporated Provides Corporate Update
    9. Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process
    10. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
    11. Genomic Health Announces Year-End 2011 Financial Results, Provides 2012 Financial Outlook
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/30/2014)... August 31, 2014 The Global ... professional and in-depth study on the current state ... and China. , The report provides a basic ... industry chain structure. Global market analysis and Chinese ... on history, developments, trends and competitive landscape of ...
    (Date:8/29/2014)... DIEGO, Aug. 29, 2014  Pfenex Inc. (NYSE ... the development of high-value and difficult to manufacture ... update and reported financial results for the second ... the successful completion of our initial public offering, ... our biosimilar product candidates, derived from our proprietary ...
    (Date:8/29/2014)... of the most promising technologies for future quantum circuits ... instead of electrons. First, it is necessary to be ... control their direction. Researchers around the world have made ... now scientists at the Niels Bohr Institute have succeeded ... at a time and in a particular direction. The ...
    (Date:8/29/2014)... The global companion diagnostics market ... It is expected to grow at a CAGR ... valued at $1.8 billion in 2013, according to ... , For more information regarding analysis details and ... research report, titled “Companion Diagnostics Market (Breast Cancer, ...
    Breaking Biology Technology:Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3
    ... VANCOUVER, Sept. 17 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. ... today that it reached a favourable,agreement with ... settle all outstanding patent litigation with respect ... agreement now in place, Angiotech expects that ...
    ... Sept. 17 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ... the,Company,s President, will present an overview of the ... 37th Annual Investment Conference,in San Francisco. Dr. Henderson,s ... 8:30 am PT. Dr. Henderson,s presentation will ...
    ... BioMed Realty Trust, Inc.,(NYSE: BMR ) today ... quarter 2007 dividend of $0.31 per share of common ... $1.24 per common share. BioMed also announced that ... per share of the company,s 7.375% Series A Cumulative,Redeemable ...
    Cached Biology Technology:Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation 2Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation 3Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation 4Keryx Biopharmaceuticals to Present at Bank of America Investment Conference 2BioMed Realty Trust Declares Third Quarter 2007 Common Stock and Preferred Stock Dividends 2
    (Date:8/29/2014)... Davis have made some surprising discoveries about the ... immunodeficiency virus (SIV), the team found that specialized ... early responders to viral invasion and are the ... called interleukin-1 beta (IL-1β). , Though aimed ... of the gut epithelium that provides a barrier ...
    (Date:8/29/2014)... Scientists at the Barshop Institute for Longevity and ... the UT Health Science Center at San Antonio, have ... the longest-lived rodent, the naked mole rat. , ... naked mole rats protects and alters the activity of ... proteins. , The factor also protects proteasome function in ...
    (Date:8/29/2014)... recently, little has been known about what genetic changes ... of scientists, one of whom is a University of ... that genes controlling the development of the brain and ... The study was published Aug. 28 in Science ... is online at http://www.sciencemag.org/ ., The domestication of ...
    Breaking Biology News(10 mins):The early cost of HIV 2Factor in naked mole rat's cells enhances protein integrity 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
    ... BMC Microbiology highlights some of the recent ... the genes involved in the complex interplay between microbes ... members of the international Plant-Associated Microbe Gene Ontology (PAMGO) ... include a language that gives researchers a shared vocabulary ...
    ... You may recall as a child catching the itchy red ... varicella zoster virus and was responsible for nearly 4 million ... (CDC), until a vaccine introduced in 1995 reduced that number ... suffered from chicken pox, the varicella zoster virus may still ...
    ... is trying to coax human stem cells to turn ... be used to replace damaged tissue in people with ... an assistant professor of chemical and molecular engineering in ... $150,000 two-year grant from the March of Dimes Foundation ...
    Cached Biology News:Special issue of BMC Microbiology spotlights standardized language for describing microbes 2Special issue of BMC Microbiology spotlights standardized language for describing microbes 3Childhood chicken pox could affect oral health years later 2Researcher seeks to turn stem cells into blood vessels 2Researcher seeks to turn stem cells into blood vessels 3
    Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6...
    ...
    ...
    Mouse Amphiregulin MAb (Clone 206220)...
    Biology Products: